
## Anticipated Emergency Use Authorization of Pfizer COVID-19 Vaccine for 5-11-year-olds October 15, 2021

As we anticipate the approval of EUA for the Pfizer COVID-19 vaccine for youth ages 5-11 years old, it is important to prepare our providers with new information ahead of the approval. This communication is intended to outline the key differences between the adult/adolescent formulation and the pediatric formulation.

The Pfizer-BioNTech vaccine for 5-11-year-olds will be a new product configuration with new packaging, new preparation, and a new national drug code (NDC). The current product for adults and adolescents should not be used in children.

The table below provides the most current information on the upcoming pediatric formulation for the Pfizer-BioNTech COVID-19 Vaccine. The new pediatric vial will come with a distinctive ORANGE cap and be filled to 1.3mL before dilution. The pediatric formulation will continue to require addition of diluent and will contain 10 doses per vial.



The packaging configuration will be 10-dose vials in cartons of 10 vials each (100 doses total) pending FDA authorization. The product will be delivered in a newly updated product shipper at -80°C (-112°F).

Once the product arrives at the provider site, it can be stored for up to 10 weeks at 2 to  $8^{\circ}$ C ( $36 - 46^{\circ}$ F) and 6 months at ultracold temperatures of -90 to  $-60^{\circ}$ C (-130 to  $-76^{\circ}$ F).

The minimum order will be 300 doses initially and 100 doses in subsequent weeks. Shipment for pediatric vaccines can begin once FDA issues the EUA, and vaccine administration can begin once ACIP makes a recommendation.

Additional information will be released as it becomes available.

Should you have any questions, please call the Maine Immunization Program at 207-287-3746.